Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

NCT04897321 is registered in ClinicalTrials.gov with St. Jude Children's Research Hospital as lead sponsor.

NCT NCT04897321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04897321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Lead sponsor
St. Jude Children's Research Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
July 6, 2022
Completion date
March 1, 2028
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adrenocortical cancer, carcinoma, clear cell sarcoma, desmoplastic small round cell tumor, ewing sarcoma, germ cell cancer, hepatoblastoma, malignant peripheral nerve sheath tumors, melanoma, neuroblastoma, osteosarcoma, pediatric solid tumor, rhabdoid tumor, rhabdomyosarcoma, soft tissue sarcoma, wilms tumor